Login to Your Account



$5M Up Front, $225M Possible

Alfacell Deals U.S. Rights for Onconase to Strativa

By Trista Morrison


Wednesday, January 16, 2008
Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription